← back to search

Matthias Fante

University Hospital Regensburg · DE
Area of research
Hematology · Oncology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, CAR-T cell therapy research, Acute Lymphoblastic Leukemia research, and Immune Cell Function and Interaction.
h-index
14
citations
1,119
works
40
NIH funding
primary concept
Medicine
email

Recent publications

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD
Blood 2025cited by 6position: middledoi
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland
Transplantation and Cellular Therapy 2025cited by 3position: middledoi
Sustained allogeneic kidney graft operational tolerance despite discontinued conventional immunosuppression after CD19-CAR-T cell therapy for relapsed/refractory posttransplant lymphoproliferative disorder
American Journal of Transplantation 2025cited by 0position: middledoi
Peripheral plasmablast expansion as a predictor and therapeutic target in chronic GVHD
Blood 2025cited by 0position: middledoi
Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy
Blood 2025cited by 0position: middledoi
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies
Haematologica 2024cited by 14position: lastdoi
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Nature Medicine 2023cited by 219position: middledoi
Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis
Transplantation and Cellular Therapy 2023cited by 12position: lastdoi
GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
Blood 2022cited by 211position: middledoi
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
Haematologica 2022cited by 24position: middledoi
All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
Frontiers in Oncology 2022cited by 5position: firstdoi
Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease
Blood 2021cited by 2position: middledoi
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
Cell Reports 2019cited by 294position: middledoi
Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib
Bone Marrow Transplantation 2018cited by 1position: firstdoi
Proton‐sensing G protein‐coupled receptors as regulators of cell proliferation and migration during tumor growth and wound healing
Experimental Dermatology 2016cited by 70position: middledoi
Metabolic plasticity of human T cells: Preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2‐deoxy‐glucose affects effector functions
European Journal of Immunology 2015cited by 88position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Daniel Wolff · Polyclinic Medical Center9 papers (2018–2025)Wolfgang Herr · Johannes Gutenberg University Mainz5 papers (2015–2025)Petra Hoffmann · University of Regensburg4 papers (2015–2025)Markus Perl · University Hospital Regensburg3 papers (2023–2025)Matthias Edinger · Polyclinic Medical Center3 papers (2023–2025)Sabine Käyser · University of Mannheim2 papers (2021–2022) · 2 papers (2021–2022) · 2 papers (2021–2022)Dennis Christoph Harrer · Friedrich-Alexander-Universität Erlangen-Nürnberg2 papers (2024–2025)Ernst Holler · Polyclinic Medical Center2 papers (2018–2023)Cristina Papayannidis · Centre Henri Becquerel2 papers (2021–2022)Bernhard Banas · University Hospital Regensburg2 papers (2023–2025)Michael Rehli · University Hospital Regensburg2 papers (2025–2025)Richard F. Schlenk · Institute of Human Genetics2 papers (2021–2022)André Gessner · University Hospital Regensburg2 papers (2025–2025)Katharina Habenicht · Friedrich-Alexander-Universität Erlangen-Nürnberg2 papers (2025–2025)Anthony D. Ho · Mayo Clinic in Arizona2 papers (2021–2022)Leo Hansmann · University Hospital Regensburg2 papers (2024–2025)Jonathan Webster · Indiana University School of Medicine2 papers (2021–2022)Andreá Schneider · Roswell Park Comprehensive Cancer Center2 papers (2025–2025)